Altria Raises Dividend Again Despite Negative Operating Cash Flow

What happened

Altria announced its 60th dividend increase in 56 years, but the decision follows a quarter with negative operating cash flow and billions in vape impairments. The company's latest 10-Q showed free cash flow of only $45 million at June 30, 2026, while first-half dividends paid totaled $3.556 billion, creating a gap between distribution and internal cash generation. Management maintains a 2.0x net debt-to-EBITDA ratio and has $3.0 billion revolver availability, providing near-term liquidity to cover the payout. However, the core cigarette business faces discount mix pressure with discount share at 33.8% and smokeable net revenue up only 0.7%, while smoke-free share remains weak with on! pouch share down 1.7 points year over year. The dividend increase signals management confidence, but it raises the question of whether the payout is being prioritized over repairing the balance sheet and investing in smoke-free transition.

Implication

Near term, Altria's liquidity and leverage support the dividend, but the negative operating cash flow and rising impairment charges indicate that the payout is increasingly reliant on balance sheet capacity rather than internal generation. The yield of 6.4% may attract income investors, but capital appreciation remains constrained by declining cigarette volumes and competitive losses in pouches and e-vapor. If the next quarterly report shows another negative free cash flow quarter or management trims guidance, the dividend's safety premium will erode and the stock could re-rate toward the bear case of $61. Conversely, if smokeable pricing holds and on! share turns positive, the income case strengthens, but that is not yet evident. We maintain a WAIT rating with a trim above $76 and an attractive entry near $63, as current evidence does not support adding at $69.50.

Thesis delta

The thesis is unchanged: Altria remains a high-yield defensive income name, but the dividend increase emphasizes management's commitment to payouts even as cash conversion weakens. The negative operating cash flow and vape impairments are consistent with our existing concern that smoke-free investments have not yet produced durable economics. This reinforces our WAIT rating and the view that the stock's 14.7x P/E already prices in dividend stability, leaving limited upside without evidence of cash flow recovery.